Learner Outcomes

Upon successful completion of the course, the Learner will be able to:

• Review the different isotopes and commonly used radiopharmaceuticals in
nuclear theranostics.

• Employ best practices for theranostic radiation safety of patients and
technologists within the regulatory requirements of the CNSC.

• Express the clinical value and basic principles of theranostic treatment of
neuroendocrine, prostate, and other diseases.

• Explain the physics involved in the theranostic dosimetry and management of
disease.

• Explore current evidence and trends related to theranostic approaches in
individualized disease management.

Course Objectives

This course is designed for medical radiation technologists (MRTs) who want to deepen
their understanding of nuclear theranostic procedures and the role of PET/CT in the
treatment planning and dosimetry monitoring of these patients. The course covers
the different therapy procedures currently being delivered for neuroendocrine tumours,
prostate cancer, leukemia and bone metastasis. It builds on the MRT’s foundational
knowledge of radiation emission and detection and explores the fundamental
aspects of alpha and beta emitters for treating disease with molecular targeted therapy.
By the end of the course, learners will better understand important procedural aspects of
nuclear theranostic procedures and the radiopharmaceuticals used in both the imaging
and therapy delivery, aiming to improve the technical quality of imaging studies,
understanding of patient dosimetry and enhance patient care quality.

Evaluation Method

Online quizzes

Intended For

Medical Radiation Technologists (MRTs)